FDA hits Neumo­ra with clin­i­cal hold for schiz­o­phre­nia drug af­ter pre­clin­i­cal da­ta showed con­vul­sions in rab­bits

Neumo­ra Ther­a­peu­tics has hit a road block to be­com­ing a ma­jor neu­ro­science play­er, with the FDA plac­ing a clin­i­cal hold on a Phase 1 study for one of its ear­ly-stage as­sets in schiz­o­phre­nia.

The com­pa­ny said that the tri­al is on hold fol­low­ing “re­cent­ly avail­able” pre­clin­i­cal da­ta for its drug dubbed NM­RA-266 which showed con­vul­sions in rab­bits. Neumo­ra said that 30 pa­tients in the Phase 1 have al­ready tak­en the drug, a mod­u­la­tor of the M4 mus­carinic re­cep­tor, and no con­vul­sions have been re­port­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER